Clinical trials: Liraglutide
Binge Eating Disorder Associated With Obesity, Binge Eating Disorder
Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity
This study is a clinical, longitudinal, non-randomized, prospective observational study that seeks to compare the treatment effects and safety of using GLP-1 analogues versus not using appetite suppressants during a lifestyle…
- Conditions
- Binge Eating Disorder Associated With Obesity, Binge Eating Disorder, Eating Disorder Binge, Eating Disorders
- Trial name
- BETTER-GLP1 (NCT07042672)
- Testing
- GLP-1, CBTe Group Therapy
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Haukeland University Hospital
Opiate Substitution Treatment, Opioid-Related Disorders
Use of a GLP-1R Agonist to Treat Opioid Use Disorder
This research is being done to find out if liraglutide (brand name is Saxenda®) can safely and effectively reduce craving for opioids in patients with opioid use disorder, a primary factor contributing to early relapse.
- Trial name
- NCT04199728
- Testing
- Liraglutide Pen Injector
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Milton S. Hershey Medical Center
Type 1 Diabetes
Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting
Hypothesis: In type 1 diabetes mellitus, in the setting of a closed loop glucose control system: adjunctive therapy with Liraglutide will afford better post-prandial glycemic excursions than insulin mono-therapy.
- Trial name
- NCT01755416
- Testing
- Closed loop with sensor and Insulin, Closed loop with sensor, Insulin and Liraglutide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Albert Einstein College of Medicine
Obesity
Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities
We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 non-diabetic obese subjects or overweight subjects with co-morbidities were randomly assigned.
- Trial name
- NCT04487743
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xiangya Hospital of Central South University
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose…
- Trial name
- DUALTM IX (NCT02773368)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 88 sites in United States, Argentina and 9 more
- Volunteers
- 420 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes
The goal of this observational retrospective study is to understand whether glucagon-like peptide-1 receptor agonists (GLP-1RA), which are a group of antidiabetes drugs, may act differently in different subtypes of patients with…
- Trial name
- NCT06120556
- Testing
- GLP-1 receptor agonist
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Type 2 Diabetes
A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes
The process of atherosclerosis is multifactorial and involves many mechanisms. The majority of published works have identified endothelial dysfunction as the first step in a cascade of events that culminates in plaque formation.
- Trial name
- ADELANTE (NCT01593137)
- Testing
- Liraglutide + metformin, Glimepiride + metformin
- Where
- Spain
- Sponsor
- Fundación Fernández-Cruz
Cushing's Disease, Acromegaly
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin.
- Trial name
- NCT02060383
- Testing
- Pasireotide s.c., Sitagliptin, Liraglutide
- Where
- 43 sites in United States, Belgium and 10 more
- Volunteers
- 249 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
This was a four-period crossover study to assess the glycemic effects of a single dose of oxyntomodulin (OXM) on the glucose levels in participants with Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01373450
- Testing
- Oxyntomodulin, Liraglutide 0.6 mg, Liraglutide 1.2 mg
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Insulin Resistance, Dementia
Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes
The purpose of this study is to evaluate the effects of liraglutide on the memory and attention of people with insulin resistance.
- Trial name
- LGT (NCT02140983)
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Stanford University
Binge-Eating Disorder
Binge Eating Liraglutide Intervention
The study is a 17-week, single-center, double-blind, parallel-group, randomized placebo controlled trial that will test the efficacy of liraglutide 3.0 mg/d as compared to placebo in reducing the number of binge episodes per…
- Trial name
- BELIEVE (NCT03279731)
- Testing
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Kelly Allison
Type 2 Diabetes
Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus
Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and the GLP-1 receptor has been found in…
- Trial name
- NCT02889510
- Testing
- liraglutide
- Where
- 6 sites in Spain
- Volunteers
- 76 people
- Sponsor
- Lecube, Albert, M.D.
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Asia. The trial is designed to compare the effect on glycaemic control of liraglutide or glimepiride added to metformin in subjects with type 2 diabetes
- Trial name
- NCT00614120
- Testing
- liraglutide, glimepiride, metformin
- Where
- 50 sites in China, India and 1 more
- Volunteers
- 929 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Liraglutide In Overweight Patients With Type 1 Diabetes
The purpose of this study is to examine the effects of liraglutide (a drug used to treat type 2 diabetes) on glucose (sugar) control over the 26 week study period when used in addition to insulin.
- Trial name
- NCT01753362
- Testing
- liraglutide
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- University at Buffalo
Type 2 Diabetes
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
Objectives: To quantify differences in control of glycemia (primary objective) and the secretion of endogenous incretin hormones (secondary objective) comparing sitagliptin or placebo added to pre-existing therapy with…
- Trial name
- NCT01937598
- Testing
- Mixed meal test, Liraglutide, Sitagliptin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Michael A. Nauck
Diabetes, Diabetes Mellitus, Type 2
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment…
- Trial name
- NCT00696657
- Testing
- semaglutide, liraglutide
- Where
- 77 sites in Austria, Bulgaria and 12 more
- Volunteers
- 415 people
- Sponsor
- Novo Nordisk A/S
Sexual Desire
Effects of Glucagon-like-Peptide-1 Analogues on Sexuality
This study is to investigate the effects of GLP-1 analogues (combined with lifestyle interventions in comparison to lifestyle interventions only) on sexual desire, mood, quality of life, the reproductive axis, retinal vessel…
- Trial name
- Desire PLUS (NCT05598008)
- Where
- Switzerland
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Type 2 Diabetes Mellitus, Overweight
Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients
Besides their potential action in the treatment of type 2 diabetes mellitus (T2DM), GLP-1 analogues decrease satiety and food intake leading to a significant weight loss in patients.
- Trial name
- NCT01599338
- Testing
- Liraglutide
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Diabetes, Diabetes Mellitus, Type 2
Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir
This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir
- Trial name
- NCT00873223
- Testing
- liraglutide, insulin detemir
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
Non-alcoholic fatty liver disease (NAFLD) is commonly associated with obesity, metabolic syndrome and type 2 diabetes. NAFLD, in patients with type 2 diabetes, has been shown to be associated with lipid abnormalities (such as…
- Trial name
- LIRA-NAFLD/LIP (NCT02721888)
- Testing
- Liraglutide, MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy), Blood sample
- Where
- France
- Volunteers
- 127 people
- Sponsor
- Centre Hospitalier Universitaire Dijon